Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06294574 · ClinicalTrials.gov registry record · NA
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
A NA study of Breast Neoplasm, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06294574: Recruiting NA study of Breast Neoplasm, sponsored by University of Alabama at Birmingham.
NCT06294574 is a NA study of Breast Neoplasm that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 150 participants, roughly in line with the 157-participant average among 26 other Breast Neoplasm trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06294574, a NA study of Breast Neoplasm, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.
Primary Outcome
The primary endpoint of HydroMARK Plus retrieval rate will be estimated with % and two-sided 95% CI using normal approximation. A paired McNemar Test will be used to compare HydroMARK Plus retrieval rate and HydroMARK retrieval rate, and the 95% CI for the difference of retrieve rate will be estimated using the Newcombe's Score method.
Conditions Studied
Interventions
- DEVICE HydroMARK Plus Clip
Study Locations (1)
Alabama
- The Kirklin Clinic - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06294574 shows while recruiting
NCT06294574 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 157-participant average among 26 other Breast Neoplasm trials with a reported enrollment target.
The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which HydroMARK Plus Clip is the first listed.
NCT06294574 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06294574 about?
NCT06294574 is a clinical study titled "Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction". The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.
What is the current status of trial NCT06294574?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-08-05. Estimated completion is 2027-12.
What conditions does trial NCT06294574 study?
This clinical trial studies the following conditions: Breast Neoplasm.
What interventions are being tested in trial NCT06294574?
The interventions under investigation include: HydroMARK Plus Clip (DEVICE).
Who is sponsoring clinical trial NCT06294574?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06294574 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06294574's enrollment target sits among peer trials
150 9th of 26 higher than 18 of 26 other Breast Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
RECRUITING · NA
-
Cryoablation vs Lumpectomy in T1 Breast Cancers
RECRUITING · NA
-
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
ACTIVE NOT RECRUITING · NA
-
Study of Web-based Decision Aids for Increasing Breast Cancer Chemoprevention in the Primary Care Setting
COMPLETED · NA
-
Post-treatment Care of Breast Cancer Survivors
COMPLETED · NA
-
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI